Skip to main content

opicapone (Ongentys®)

 

Following a full submission

AWMSG advice

Status: Recommended with restrictions

Opicapone (Ongentys®) is recommended as an option for restricted use within NHS Wales. 

Opicapone (Ongentys®) is licensed for use within NHS Wales as an adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Opicapone (Ongentys®) is restricted within the licensed indication for use after failure of entacapone, or in patients who cannot tolerate entacapone. 

Opicapone (Ongentys®) is not recommended for use within NHS Wales as a first-line catechol-O-methyltransferase (COMT) inhibitor and should only be used after entacapone.

This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.

 Final Recommendation: opicapone (Ongentys) 911 (PDF, 302Kb)
 Appraisal Report: opicapone (Ongentys) 911 (PDF, 302Kb)

Medicine details

Medicine name opicapone (Ongentys®)
Formulation 50 mg capsule
Reference number 911
Indication

Adjunctive therapy to preparations of levodopa/DOPA decarboxylase inhibitors (DDCIs) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations

Company Bial - Portela C SA
BNF chapter Central nervous system
Submission type Full
Status Recommended with restrictions
Advice number 0121
NMG meeting date 06/01/2021
AWMSG meeting date 09/02/2021
Date of issue 17/03/2021
Commercial arrangement WPAS